Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for hypothalamic obesity after craniopharyngioma therapy
2013-004755-21Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypothalamic obesity (HO) comparing Exenatide + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Primary endpoint: Weight variation at 6 months. Started Mar 2016; status: completed.
02
Drugs
exenatide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on 2013-004755-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004755-21.